Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.

de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus F, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV.

Eur J Endocrinol. 2019 Jul 1. pii: EJE-19-0291.R1. doi: 10.1530/EJE-19-0291. [Epub ahead of print]

2.

Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.

Ahmed S, Cerosaletti K, James E, Long SA, Mannering S, Speake C, Nakayama M, Tree T, Roep BO, Herold KC, Brusko TM.

Diabetes. 2019 Jul;68(7):1366-1379. doi: 10.2337/db19-0119.

PMID:
31221801
3.

Activated Mesenchymal Stromal Cells Process and Present Antigens Regulating Adaptive Immunity.

van Megen KM, van 't Wout ET, Lages Motta J, Dekker B, Nikolic T, Roep BO.

Front Immunol. 2019 Apr 3;10:694. doi: 10.3389/fimmu.2019.00694. eCollection 2019.

4.

Persistent C-peptide is associated with reduced hypoglycaemia but not HbA1c in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?

Marren SM, Hammersley S, McDonald TJ, Shields BM, Knight BA, Hill A, Bolt R, Tree TI, Roep BO, Hattersley AT, Jones AG, Oram RA; TIGI consortium.

Diabet Med. 2019 Sep;36(9):1092-1099. doi: 10.1111/dme.13960. Epub 2019 Jun 27.

PMID:
30955221
5.

Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy.

Dul M, Nikolic T, Stefanidou M, McAteer MA, Williams P, Mous J, Roep BO, Kochba E, Levin Y, Peakman M, Wong FS, Dayan CM, Tatovic D, Coulman SA, Birchall JC; EE-ASI Consortium.

Int J Pharm. 2019 May 1;562:303-312. doi: 10.1016/j.ijpharm.2019.03.041. Epub 2019 Mar 22.

PMID:
30910633
6.

Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells.

Furuyama K, Chera S, van Gurp L, Oropeza D, Ghila L, Damond N, Vethe H, Paulo JA, Joosten AM, Berney T, Bosco D, Dorrell C, Grompe M, Ræder H, Roep BO, Thorel F, Herrera PL.

Nature. 2019 Mar;567(7746):43-48. doi: 10.1038/s41586-019-0942-8. Epub 2019 Feb 13.

7.

Epitope Stealing as a Mechanism of Dominant Protection by HLA-DQ6 in Type 1 Diabetes.

van Lummel M, Buis DTP, Ringeling C, de Ru AH, Pool J, Papadopoulos GK, van Veelen PA, Reijonen H, Drijfhout JW, Roep BO.

Diabetes. 2019 Apr;68(4):787-795. doi: 10.2337/db18-0501. Epub 2019 Jan 9.

8.

Bioluminescent reporter assay for monitoring ER stress in human beta cells.

Kracht MJL, de Koning EJP, Hoeben RC, Roep BO, Zaldumbide A.

Sci Rep. 2018 Dec 10;8(1):17738. doi: 10.1038/s41598-018-36142-4.

9.

Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine.

Roep BO, Wheeler DCS, Peakman M.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):65-74. doi: 10.1016/S2213-8587(18)30109-8. Epub 2018 Oct 24. Review.

PMID:
30528100
10.

The challenge of modulating β-cell autoimmunity in type 1 diabetes.

Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64. doi: 10.1016/S2213-8587(18)30112-8. Epub 2018 Oct 24. Review.

PMID:
30528099
11.

Syntaxin 4 Expression in Pancreatic β-Cells Promotes Islet Function and Protects Functional β-Cell Mass.

Oh E, Ahn M, Afelik S, Becker TC, Roep BO, Thurmond DC.

Diabetes. 2018 Dec;67(12):2626-2639. doi: 10.2337/db18-0259. Epub 2018 Oct 10.

12.

Association between maternal gluten intake and type 1 diabetes in offspring: national prospective cohort study in Denmark.

Antvorskov JC, Halldorsson TI, Josefsen K, Svensson J, Granström C, Roep BO, Olesen TH, Hrolfsdottir L, Buschard K, Olsen SF.

BMJ. 2018 Sep 19;362:k3547. doi: 10.1136/bmj.k3547.

13.

Islet stress, degradation and autoimmunity.

Thomaidou S, Zaldumbide A, Roep BO.

Diabetes Obes Metab. 2018 Sep;20 Suppl 2:88-94. doi: 10.1111/dom.13387. Review.

14.

Islet Allotransplantation in the Bone Marrow of Patients With Type 1 Diabetes: A Pilot Randomized Trial.

Maffi P, Nano R, Monti P, Melzi R, Sordi V, Mercalli A, Pellegrini S, Ponzoni M, Peccatori J, Messina C, Nocco A, Cardillo M, Scavini M, Magistretti P, Doglioni C, Ciceri F, Bloem SJ, Roep BO, Secchi A, Piemonti L.

Transplantation. 2019 Apr;103(4):839-851. doi: 10.1097/TP.0000000000002416.

PMID:
30130323
15.

Heterogeneity of circulating CD8 T-cells specific to islet, neo-antigen and virus in patients with type 1 diabetes mellitus.

Laban S, Suwandi JS, van Unen V, Pool J, Wesselius J, Höllt T, Pezzotti N, Vilanova A, Lelieveldt BPF, Roep BO.

PLoS One. 2018 Aug 8;13(8):e0200818. doi: 10.1371/journal.pone.0200818. eCollection 2018.

16.

C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase.

Shields BM, McDonald TJ, Oram R, Hill A, Hudson M, Leete P, Pearson ER, Richardson SJ, Morgan NG, Hattersley AT; TIGI Consortium.

Diabetes Care. 2018 Jul;41(7):1486-1492. doi: 10.2337/dc18-0465. Epub 2018 Jun 7.

17.

A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes.

van Megen KM, van 't Wout ET, Forman SJ, Roep BO.

Front Immunol. 2018 Apr 6;9:690. doi: 10.3389/fimmu.2018.00690. eCollection 2018. No abstract available.

18.

SLC30A8 polymorphism and BMI complement HLA-A*24 as risk factors for poor graft function in islet allograft recipients.

Balke EM, Demeester S, Lee D, Gillard P, Hilbrands R, Van de Velde U, Van der Auwera BJ, Ling Z, Roep BO, Pipeleers DG, Keymeulen B, Gorus FK.

Diabetologia. 2018 Jul;61(7):1623-1632. doi: 10.1007/s00125-018-4609-z. Epub 2018 Apr 20.

PMID:
29679103
19.

Abnormal islet sphingolipid metabolism in type 1 diabetes.

Holm LJ, Krogvold L, Hasselby JP, Kaur S, Claessens LA, Russell MA, Mathews CE, Hanssen KF, Morgan NG, Koeleman BPC, Roep BO, Gerling IC, Pociot F, Dahl-Jørgensen K, Buschard K.

Diabetologia. 2018 Jul;61(7):1650-1661. doi: 10.1007/s00125-018-4614-2. Epub 2018 Apr 18.

20.

Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials.

Suwandi JS, Nikolic T, Roep BO.

Front Immunol. 2017 Nov 22;8:1598. doi: 10.3389/fimmu.2017.01598. eCollection 2017. Review.

21.

Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study.

de Groot PF, Belzer C, Aydin Ö, Levin E, Levels JH, Aalvink S, Boot F, Holleman F, van Raalte DH, Scheithauer TP, Simsek S, Schaap FG, Olde Damink SWM, Roep BO, Hoekstra JB, de Vos WM, Nieuwdorp M.

PLoS One. 2017 Dec 6;12(12):e0188475. doi: 10.1371/journal.pone.0188475. eCollection 2017.

22.

Erratum to: Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M.

Diabetologia. 2017 Dec;60(12):2540. doi: 10.1007/s00125-017-4446-5. No abstract available.

PMID:
28948305
23.

Type 1 diabetes induction in humanized mice.

Tan S, Li Y, Xia J, Jin CH, Hu Z, Duinkerken G, Li Y, Khosravi Maharlooei M, Chavez E, Nauman G, Danzl N, Nakayama M, Roep BO, Sykes M, Yang YG.

Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10954-10959. doi: 10.1073/pnas.1710415114. Epub 2017 Sep 5.

24.

Relapsing/remitting type 1 diabetes.

van Megen KM, Spindler MP, Keij FM, Bosch I, Sprangers F, van Royen-Kerkhof A, Nikolic T, Roep BO.

Diabetologia. 2017 Nov;60(11):2252-2255. doi: 10.1007/s00125-017-4403-3. Epub 2017 Aug 23.

25.

Differential transcriptome of tolerogenic versus inflammatory dendritic cells points to modulated T1D genetic risk and enriched immune regulation.

Nikolic T, Woittiez NJC, van der Slik A, Laban S, Joosten A, Gysemans C, Mathieu C, Zwaginga JJ, Koeleman B, Roep BO.

Genes Immun. 2017 Sep;18(3):176-183. doi: 10.1038/gene.2017.18. Epub 2017 Aug 10.

PMID:
28794505
26.

Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M.

Diabetologia. 2017 Nov;60(11):2139-2147. doi: 10.1007/s00125-017-4384-2. Epub 2017 Aug 2. Review. Erratum in: Diabetologia. 2017 Sep 26;:.

27.

The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes.

Bloem SJ, Roep BO.

Diabetologia. 2017 Jul;60(7):1185-1189. doi: 10.1007/s00125-017-4284-5. Epub 2017 Apr 24.

PMID:
28439640
28.

Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes.

Malmegrim KC, de Azevedo JT, Arruda LC, Abreu JR, Couri CE, de Oliveira GL, Palma PV, Scortegagna GT, Stracieri AB, Moraes DA, Dias JB, Pieroni F, Cunha R, Guilherme L, Santos NM, Foss MC, Covas DT, Burt RK, Simões BP, Voltarelli JC, Roep BO, Oliveira MC.

Front Immunol. 2017 Feb 22;8:167. doi: 10.3389/fimmu.2017.00167. eCollection 2017.

29.

Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes.

Kracht MJ, van Lummel M, Nikolic T, Joosten AM, Laban S, van der Slik AR, van Veelen PA, Carlotti F, de Koning EJ, Hoeben RC, Zaldumbide A, Roep BO.

Nat Med. 2017 Apr;23(4):501-507. doi: 10.1038/nm.4289. Epub 2017 Feb 27.

PMID:
28263308
30.

Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes.

Michels AW, Landry LG, McDaniel KA, Yu L, Campbell-Thompson M, Kwok WW, Jones KL, Gottlieb PA, Kappler JW, Tang Q, Roep BO, Atkinson MA, Mathews CE, Nakayama M.

Diabetes. 2017 Mar;66(3):722-734. doi: 10.2337/db16-1025. Epub 2016 Dec 5.

31.

Immunogenicity of human embryonic stem cell-derived beta cells.

van der Torren CR, Zaldumbide A, Duinkerken G, Brand-Schaaf SH, Peakman M, Stangé G, Martinson L, Kroon E, Brandon EP, Pipeleers D, Roep BO.

Diabetologia. 2017 Jan;60(1):126-133. Epub 2016 Oct 27.

32.

Identification of Donor Origin and Condition of Transplanted Islets In Situ in the Liver of a Type 1 Diabetic Recipient.

van der Torren CR, Suwandi JS, Lee D, Van't Wout ET, Duinkerken G, Swings G, Mulder A, Claas FH, Ling Z, Gillard P, Keymeulen B, In't Veld P, Roep BO.

Cell Transplant. 2017 Jan 24;26(1):1-9. doi: 10.3727/096368916X693437. Epub 2016 Oct 10.

33.

A roadmap of the generation of neoantigens as targets of the immune system in type 1 diabetes.

Roep BO, Kracht MJ, van Lummel M, Zaldumbide A.

Curr Opin Immunol. 2016 Dec;43:67-73. doi: 10.1016/j.coi.2016.09.007. Epub 2016 Oct 7. Review.

34.

Survival of autoreactive T lymphocytes by microRNA-mediated regulation of apoptosis through TRAIL and Fas in type 1 diabetes.

de Jong VM, van der Slik AR, Laban S, van 't Slot R, Koeleman BP, Zaldumbide A, Roep BO.

Genes Immun. 2016 Sep;17(6):342-8. doi: 10.1038/gene.2016.29. Epub 2016 Jul 28.

PMID:
27467285
35.

HLA-A*24 Carrier Status and Autoantibody Surges Posttransplantation Associate With Poor Functional Outcome in Recipients of an Islet Allograft.

Demeester S, Balke EM, Van der Auwera BJ, Gillard P, Hilbrands R, Lee D, Van de Velde U, Ling Z, Roep BO, Pipeleers DG, Gorus FK, Keymeulen B.

Diabetes Care. 2016 Jun;39(6):1060-4. doi: 10.2337/dc15-2768. Epub 2016 Apr 26.

PMID:
27208324
36.

Where, How, and When: Positioning Posttranslational Modification Within Type 1 Diabetes Pathogenesis.

McLaughlin RJ, Spindler MP, van Lummel M, Roep BO.

Curr Diab Rep. 2016 Jul;16(7):63. doi: 10.1007/s11892-016-0752-4. Review.

37.

Neoantigens and Microenvironment in Type 1 Diabetes: Lessons from Antitumor Immunity.

Kracht MJL, Zaldumbide A, Roep BO.

Trends Endocrinol Metab. 2016 Jun;27(6):353-362. doi: 10.1016/j.tem.2016.03.013. Epub 2016 Apr 16. Review.

PMID:
27094501
38.

Dendritic Cells Guide Islet Autoimmunity through a Restricted and Uniquely Processed Peptidome Presented by High-Risk HLA-DR.

van Lummel M, van Veelen PA, de Ru AH, Janssen GM, Pool J, Laban S, Joosten AM, Nikolic T, Drijfhout JW, Mearin ML, Aanstoot HJ, Peakman M, Roep BO.

J Immunol. 2016 Apr 15;196(8):3253-63. doi: 10.4049/jimmunol.1501282. Epub 2016 Mar 4.

39.

Insulitis Revisited.

Roep BO.

Diabetes. 2016 Mar;65(3):545-7. doi: 10.2337/dbi15-0040. No abstract available.

40.

Human islets and dendritic cells generate post-translationally modified islet autoantigens.

McLaughlin RJ, de Haan A, Zaldumbide A, de Koning EJ, de Ru AH, van Veelen PA, van Lummel M, Roep BO.

Clin Exp Immunol. 2016 Aug;185(2):133-40. doi: 10.1111/cei.12775. Epub 2016 May 17.

41.

Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 Diabetes.

van der Torren CR, Verrijn Stuart AA, Lee D, Meerding J, van de Velde U, Pipeleers D, Gillard P, Keymeulen B, de Jager W, Roep BO.

PLoS One. 2016 Jan 11;11(1):e0146649. doi: 10.1371/journal.pone.0146649. eCollection 2016.

42.

Discovery of a Selective Islet Peptidome Presented by the Highest-Risk HLA-DQ8trans Molecule.

van Lummel M, van Veelen PA, de Ru AH, Pool J, Nikolic T, Laban S, Joosten A, Drijfhout JW, Gómez-Touriño I, Arif S, Aanstoot HJ, Peakman M, Roep BO.

Diabetes. 2016 Mar;65(3):732-41. doi: 10.2337/db15-1031. Epub 2015 Dec 30.

43.

Variation in the CTLA4 3'UTR has phenotypic consequences for autoreactive T cells and associates with genetic risk for type 1 diabetes.

de Jong VM, Zaldumbide A, van der Slik AR, Laban S, Koeleman BP, Roep BO.

Genes Immun. 2016 Jan-Feb;17(1):75-8. doi: 10.1038/gene.2015.51. Epub 2015 Dec 10.

PMID:
26656450
44.

Multiple autoantibodies at onset do not accurately predict long-term pancreatic beta-cell fate in a 13-year-old obese child with immediate insulin-requiring diabetes.

Marchand L, Nicolino M, Fabien N, Roep BO, Thivolet C.

Diabetes Metab. 2016 Feb;42(1):69-70. doi: 10.1016/j.diabet.2015.10.006. Epub 2015 Nov 24. No abstract available.

PMID:
26619919
45.

Innate and adaptive immunity to human beta cell lines: implications for beta cell therapy.

van der Torren CR, Zaldumbide A, Roelen DL, Duinkerken G, Brand-Schaaf SH, Peakman M, Czernichow P, Ravassard P, Scharfmann R, Roep BO.

Diabetologia. 2016 Jan;59(1):170-175. doi: 10.1007/s00125-015-3779-1.

46.

Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells.

Suwandi JS, Toes RE, Nikolic T, Roep BO.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S97-103. Epub 2015 Oct 12. Review.

PMID:
26458178
47.

T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex.

Beringer DX, Kleijwegt FS, Wiede F, van der Slik AR, Loh KL, Petersen J, Dudek NL, Duinkerken G, Laban S, Joosten A, Vivian JP, Chen Z, Uldrich AP, Godfrey DI, McCluskey J, Price DA, Radford KJ, Purcell AW, Nikolic T, Reid HH, Tiganis T, Roep BO, Rossjohn J.

Nat Immunol. 2015 Nov;16(11):1153-61. doi: 10.1038/ni.3271. Epub 2015 Oct 5.

PMID:
26437244
48.

Vitamin D receptor polymorphisms and growth until adulthood after very premature birth.

Finken MJ, Schrevel M, Houwing-Duistermaat JJ, Kharagjitsingh AV, Dekker FW, Koeleman BP, Roep BO, Wit JM.

J Bone Miner Metab. 2016 Sep;34(5):564-70. doi: 10.1007/s00774-015-0697-8. Epub 2015 Jul 28.

PMID:
26212485
49.

Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model.

Gibson VB, Nikolic T, Pearce VQ, Demengeot J, Roep BO, Peakman M.

Clin Exp Immunol. 2015 Dec;182(3):251-60. doi: 10.1111/cei.12687. Epub 2015 Sep 17.

50.

Proteasomal Degradation of Proinsulin Requires Derlin-2, HRD1 and p97.

Hoelen H, Zaldumbide A, van Leeuwen WF, Torfs EC, Engelse MA, Hassan C, Lebbink RJ, de Koning EJ, Resssing ME, de Ru AH, van Veelen PA, Hoeben RC, Roep BO, Wiertz EJ.

PLoS One. 2015 Jun 24;10(6):e0128206. doi: 10.1371/journal.pone.0128206. eCollection 2015.

Supplemental Content

Loading ...
Support Center